EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Bacteriophage therapy for antimicrobial-resistant, biofilm‑associated diabetic foot infection: delivery routes, phage antibiotic synergy, and practical wound‑care integration

Muhammad Irbaz, Zunaira Hamood, Summayah Shahid, Afra Ghufran, Aamir Ajmal, Iqra Rafiq

Archives of Microbiology · 2026-11 · 208 (11)

DOI: 10.1007/s00203-026-05134-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Microbiology, online erschienen am 18.08.2026. Verfasst von Muhammad Irbaz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Veterinary Science, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, 63100, Pakistan. Hauptthemen laut MEDLINE: Phage Therapy, Diabetic Foot, Biofilms, Anti-Bacterial Agents. Die Arbeit nennt 134 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic foot infections (DFIs) are a significant public health problem, associated with a delayed healing process and high rates of recurrence, which culminates in amputation. Two main factors, antimicrobial resistance (AMR) and biofilm formation, are responsible for the persistence and therapeutic failure of DFIs, resulting in extended healing time, infection recurrence, and an increased risk of amputation. In addition, the emergence of multidrug-resistant (MDR) pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa has made traditional antibiotic treatment less effective, necessitating alternative or adjunctive therapy. Phage therapy is an alternative approach to treat biofilm-associated and antimicrobial-resistant DFIs. Bacteriophages, viruses that infect bacteria, are highly specific to their bacterial hosts, can disrupt biofilms, and increase the activity of antimicrobial drugs used alone or in combination. This review focuses on the therapeutic potential of phage-based interventions for AMR and biofilm-related DFIs, highlighting delivery methods, phage-antibiotic synergy (PAS), incorporation into wound care regimens, and novel translational potential. Further interest in phage-based therapeutics has grown with recent advances in engineered phages, phage-derived enzymes, and precision diagnostics. Clinical and preclinical data indicate that phage therapy may be a promising strategy to improve bacterial control in specific DFI applications. Experimental studies have shown activity against MDR pathogens and biofilm-associated infections, and early clinical reports show potential for therapeutic benefit. The evidence base is currently small and is skewed towards in vitro studies, animal models, case reports, and small clinical trials. However, significant clinical evidenceis still needed before they can be widely adopted. There are several important barriers, such as the absence of large-scale randomized controlled trials, standardized treatment protocols, manufacturing consistency, and harmonized regulatory frameworks. Rigorous clinical evaluation, enhanced diagnostics (e.g., metagenomics profiling), delivery optimization, and regulatory coordination will be the key factors for further progress. Together, these advances could facilitate the integration of phage therapy into a multidisciplinary approach to DFI treatment and improve outcomes for patients with complex biofilm-related and AMR infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phage TherapyDiabetic FootBiofilmsAnti-Bacterial AgentsBacteriophagesBacterial InfectionsHumansAnimalsDrug Resistance, Multiple, BacterialPseudomonas aeruginosaBacteria

Stichwörter der Autor:innen

Antimicrobial resistanceBacteriophage therapyBiofilm-associated infectionsDiabetic foot infectionsPhage-antibiotic synergy

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pathology, Faculty of Veterinary Science, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, 63100, Pakistan.
  • Department of Microbiology and Molecular Genetics, University of the Punjab, Quaid-e-Azam Campus, Lahore, 54590, Pakistan.
  • Department of Microbiology, Faculty of Biological Sciences, Quaid-e-Azam University, Islamabad, 45320, Pakistan.
  • Institute of Microbiology, Faculty of Veterinary Sciences, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan.
  • Center of Biotechnology and Microbiology, University of Peshawar, Peshawar, 25120, Pakistan.
  • Department of Microbiology, Faculty of Veterinary and Animal Science, The Islamia University of Bahawalpur, 63100, Bahawalpur, Punjab, Pakistan. ummehoorain92@gmail.com.

Zitieren

APA

Irbaz, M., Hamood, Z., Shahid, S., Ghufran, A., Ajmal, A., & Rafiq, I. (2026). Bacteriophage therapy for antimicrobial-resistant, biofilm‑associated diabetic foot infection: delivery routes, phage antibiotic synergy, and practical wound‑care integration. Archives of Microbiology, 208(11). https://doi.org/10.1007/s00203-026-05134-8

Vancouver

Irbaz M, Hamood Z, Shahid S, Ghufran A, Ajmal A, Rafiq I. Bacteriophage therapy for antimicrobial-resistant, biofilm‑associated diabetic foot infection: delivery routes, phage antibiotic synergy, and practical wound‑care integration. Archives of Microbiology. 2026;208(11). doi:10.1007/s00203-026-05134-8

BibTeX
@article{Irbaz2026,
  author = {Irbaz, Muhammad and Hamood, Zunaira and Shahid, Summayah and Ghufran, Afra and Ajmal, Aamir and Rafiq, Iqra},
  title = {Bacteriophage therapy for antimicrobial-resistant, biofilm‑associated diabetic foot infection: delivery routes, phage antibiotic synergy, and practical wound‑care integration},
  journal = {Archives of Microbiology},
  year = {2026},
  volume = {208},
  number = {11},
  doi = {10.1007/s00203-026-05134-8}
}
Kostenlos starten →